RecruitingPhase 2NCT06893783

Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

Studying Neuroendocrine carcinoma of pancreas

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Inkeun Park
Principal Investigator: Inkeun Park, M.D, Ph D, M.D
Asan Medical Center
Intervention: Tarlatamab(drug)
Enrollment: 60 enrolled
Eligibility: 19 years · All sexes
Timeline: 2025 – 2029

Study locations (4)

Asan Medical Center, Seoul, South Korea
Samsung Medical Center, Seoul, South Korea
Seoul National University Hospital, Seoul, South Korea
Yonsei Severance Hospital, Seoul, South Korea

Collaborators

Seoul National University Hospital · Severance Hospital · Samsung Medical Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06893783 on ClinicalTrials.gov

← Back to all trials